Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials
- Updated on: 2022-06-14
- Read original article here
Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials
Metrics details
Abstract
No pharmacotherapeutic agents are yet recommended for active CN though many anti-resorptive agents have been studied. We conducted a systematic review and meta-analysis of the randomized placebo-controlled trials (RCTs) evaluating the time to remission of active CN with anti-resorptive or antiinflammatory drugs. RCTs published in PubMed, EMBASE, SCOPUS and Cochrane Library from January 1994 to December 2019 were accessed. We reviewed studies and extracted information on study design, participants’ characteristics, time to remission, bone turnover markers, bone mineral content (BMC) and temperature difference between feet. Five RCTs out of 588 total identified records were included. Standardized mean differences (SMD) between groups with 95% CI are summarized. Pharmacotherapy nonsignificantly increased time to remission [SMD 0.52 weeks (− 0.71, 1.75), p = 0.402; I2 = 88.6%] as compared to TCC alone. The pooled median time to remission with the intervention was 18.5 weeks (11.2, 28.1) compared to 16.8 weeks (8.7, 27.7) with TCC. A nonsignificant increase in BMC [SMD 3.39% (− 0.78, 7.56), p = 0.109; I2 = 96.7%], a decrease in foot temperature [SMD − 0.42 °C (− 0.78, − 0.07), p = 0.020; I2 = 0%] and alkaline phosphatase [SMD = −2.51% (− 3.24, − 1.77), p < 0.001; I2 = 0%] was observed with intervention. Limited evidence from available studies does not support the role of anti-resorptive or anti-inflammatory drugs for earlier remission when added to offloading with total contact cast for active CN of the foot.
This is a preview of subscription content, log in to check access.
Access options
Instant access to the full article PDF.
US$ 39.95
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
US$ 79
Fig. 4
Data availability
The data supporting the finding of the present study are available from the corresponding author upon reasonable request.
References
1.
Wukich DK, Sung W, Wipf SA, Armstrong DG (2011) The consequences of complacency: managing the effects of unrecognized Charcot feet. Diabetes Med 28(2):195–198
CAS Article Google Scholar
2.
Sohn MW, Stuck RM, Pinzur M, Lee TA, Budiman-Mak E (2010) Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer. Diabetes Care 33(1):98–100. https://doi.org/10.2337/dc09-1497
PubMed Article Google Scholar
3.
Rastogi A, Goyal G, Kesavan R et al (2020) Long term outcomes after incident diabetic foot ulcer: multicenter large cohort prospective study (EDI-FOCUS investigators) epidemiology of diabetic foot complications study. Diabetes Res Clin Pract 162:108113. https://doi.org/10.1016/j.diabres.2020.108113
PubMed Article Google Scholar
4.
Baal JV, Hubbard R, Game F, Jeffcoate W (2010) Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care 33:1086–1089
PubMed PubMed Central Article Google Scholar
5.
Chaudhary S, Bhansali A, Rastogi A (2019) Mortality in Asian Indians with Charcot’s neuroarthropathy: a nested cohort prospective study. Acta Diabetol 56(12):1259–1264
CAS PubMed Article Google Scholar
7.
Moura-Neto A, Fernandes TD, Zantut-Witmann DE et al (2012) Charcot foot: skin temperature as a good clinical parameter for predicting disease outcome. Diabetes Res Clin Pract 96:e11–e14
PubMed Article Google Scholar
8.
Game FL, Catlow R, Jones GR et al (2012) Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia 55:32–35
CAS PubMed Article Google Scholar
9.
Christensen TM, Gade-Rasmussen B, Pedersen LW, Hommel E, Holstein PE, Svendsen OL (2012) Duration of off-loading and recurrence rate in Charcot osteoarthropathy treated with less restrictive regimen with removable walker. J Diabetes Complic 26:430–434
Article Google Scholar
10.
Wennberg L, Lundgren P, Axelsson R, Aspelin P, Gerok-Andersson K, Åkerlund B (2017) Diabetic osteoarthropathy care in Sweden—need for improvement: a national inventory. J Clin Transl Endocrinol 9:32–37
PubMed PubMed Central Google Scholar
11.
Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058–2061
CAS PubMed Article Google Scholar
12.
Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A (2008) Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 51:1035–1040
CAS PubMed PubMed Central Article Google Scholar
13.
Folestad A, Alund M, Asteberg S (2015) Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Acta Orthop 86(4):415–425
PubMed PubMed Central Article Google Scholar
14.
Bruhn-Olszewska B, Korzon-Burakowska A, Węgrzyn G, Jakóbkiewicz-Banecka J (2017) Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development. Sci Rep 29(1):1–9
CAS PubMed Article Google Scholar
16.
Jude EB, Selby PL, Burgess J et al (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032–2037
CAS PubMed Article Google Scholar
17.
Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A et al (2005) Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 28:1214–1215
CAS PubMed Article Google Scholar
18.
Bem R, Jirkovská A, Fejfarová V, Skibová J, Jude EB (2006) Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 29:1392–1394
CAS PubMed Article Google Scholar
19.
Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J (2011) The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care 34:1514–1516
CAS PubMed PubMed Central Article Google Scholar
20.
Rogers LC, Frykberg RG, Armstrong DG et al (2011) The Charcot foot in diabetes. Diabetes Care 34(9):2123–2129
PubMed PubMed Central Article Google Scholar
21.
Richard JL, Almasri M, Schuldiner S (2012) Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature. Diabetologia 55:1258–1264
CAS PubMed Article Google Scholar
22.
Busch-Westbroek TE, Delpeut K, Balm R et al (2018) Effect of single dose of RANKL antibody treatment on acute Charcot neuro-osteoarthropathy of the foot. Diabetes Care 41:e21–e22
CAS PubMed Article Google Scholar
23.
Das L, Bhansali A, Prakash M, Jude E, Rastogi A (2019) Effect of methylprednisolone or zoledronic acid for the resolution of active Charcot neuroarthropathy in diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Care 42:e1–e2. https://doi.org/10.2337/dc19-1659
CAS Article Google Scholar
24.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012
PubMed PubMed Central Article Google Scholar
25.
Rastogi A, Bhansali A, Jude EB. Efficacy of medical treatment for active Charcot neuroarthropathy of foot: Systematic Review And Meta-Analysis. PROSPERO 2020 CRD42020164615. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020164615 . Accessed 25 Apr 2020
26.
Selby PL, Young MJ, Adams JE, Boulton AJM (1994) Bisphosphonate: a new treatment for diabetic Charcot neuroarthropathy. Diabet Med 11:14–20
Article Google Scholar
27.
Bharat R, Bal A, Sundaram S et al (2013) A comparative study of zoledronic acid and alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus. Ind J Endocrinol Metab 17:110–116
Article Google Scholar
28.
Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM (2004) Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 43:285–289
PubMed Article Google Scholar
29.
Vopat ML, Nentwig MJ, Chong ACM, Agan JL, Shields NN, Yang SY (2018) Initial diagnosis and management for acute Charcot neuroarthropathy. Kans J Med 11(4):114–119
PubMed PubMed Central Article Google Scholar
30.
Rastogi A, Prakash M, Bhansali A (2019) Varied presentations and outcomes of Charcot neuroarthropathy in patients with diabetes. Int J Diabetes Dev Ctries 39(3):513–522
Article Google Scholar
31.
Armstrong DG, Lavery LA (1997) Monitoring healing of acute Charcot’s arthropathy with infrared dermal thermometry. J Rehabil Res Dev 34:317–321
CAS PubMed Google Scholar
32.
Hastings MK, Sinacore DR, Fielder FA, Johnson JE (2005) Bone mineral density during total contact cast immobilization for a patient with neuropathic (Charcot) arthropathy. PhyTher 85(3):249–256
Google Scholar
37.
Stansberry KB et al (1999) Intravenous biphosphonate rapidly reverses the paradoxical increase in blood flow to the foot in Charcot neuropathy (abstr). Diabetes 48(suppl 1):A92
Google Scholar
38.
Guis S, Pellissier JF, Amiaud D et al (1999) Healing of Charcot’s joint by pamidronate infusion. J Rheum 26:1843–1845
CAS PubMed Google Scholar
39.
Rastogi A, Hajela A, Prakash M et al (2019) Teriparatide (recombinant human parathyroid hormone [1-34]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study. J Diabetes 11(9):703–710
CAS PubMed Article Google Scholar
40.
Anastasilakis AD, Polyzos SA, Makras P (2018) THERAPY OF ENDOCRINE DISEASE: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol 179(1):R31–R45
CAS PubMed Article Google Scholar
41.
Kendler DL, Roux C, Benhamou CL et al (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25(1):72–81
CAS PubMed Article Google Scholar
42.
Anastasilakis AD, Polyzos SA, Gkiomisi A et al (2015) Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int 26(10):2521–2527
CAS PubMed Article Google Scholar
43.
Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163–3170
